Lung cancer gene test without surgery shows promise
NCT ID NCT01487603
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a small sample taken from lung cancer patients during a routine biopsy (called EBUS-TBNA) can be used to analyze genes that predict how well treatments like chemotherapy or surgery might work. Researchers plan to enroll 400 adults with confirmed or suspected lung cancer. The goal is to see if this less invasive method can replace surgery for getting the genetic information needed to personalize treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors choose more effective treatments for lung cancer patients without needing surgery.
- What could go wrong
- This is an early feasibility study, not a treatment trial. It may not lead to immediate changes in care, and the gene analysis might not always be accurate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Oct 2011
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with lung cancer
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older. * Patients with confirmed or suspected lung cancer who require EBUS-TBNA as part of their staging investigations of the mediastinum will be considered for the trial. * Patients with undiagnosed enlarged lymph nodes in the mediastinum suspicious for lung cancer in which a tissue diagnosis is required. Exclusion Criteria: * Patients who are deemed on clinical grounds not to be medically fit for a bronchoscopy. * Patients where there is a high clinical suspicion of lymphoma.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Health Network
RECRUITINGToronto, Ontario, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an Anti-Fibrotic drug shield lungs from radiation after immunotherapy?
- App aims to catch a hidden radiotherapy side effect
- Which nerve block wins for lung surgery pain?
- Amazon plant put to the test against Cancer's relentless tiredness
- Can a virtual stress program help working spouses care for cancer patients without burning out?
- Freezing probe aims to kill lung tumors through the airways